Morphine plus midazolam versus oxygen therapy on severe dyspnea management in the last week of life in hipoxemic advanced cancer patients;Morfina más midazolan versus oxigenoterapia en el control de la disnea severa durante la última semana de vida en pacientes hipoxémicos con cáncer avanzado

Medicina Paliativa

Volumn 10, Issue 1, 2003, Pages 14-19

  Navigante, A H ^a   Cerchietti, Leandro C A ^a   Cabalar, Ma E ^a  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Cancer; Dyspnea; Midazolam; Morphine; Oxygen

Indexed keywords

MIDAZOLAM; MORPHINE; OXYGEN;

ADULT; ADVANCED CANCER; AGED; ANALGESIA; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG CHOICE; DRUG EFFICACY; DYSPNEA; FACE MASK; FEMALE; HUMAN; HYPOXEMIA; INTERMETHOD COMPARISON; MALE; MAXIMUM TOLERATED DOSE; OXYGEN BLOOD LEVEL; OXYGEN SATURATION; OXYGEN THERAPY; PANIC; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TERMINAL CARE; TREATMENT OUTCOME;

EID: 0037241681     PISSN: 1134248X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Reuben DB, Mor V. Dyspnea in terminally ill cancer patients. Chest 1986; 89: 234-6.
2. Higginson I, McCarthy M. Measuring symptoms in terminal cancer: are pain and dyspnea controlled? J Royal Society Med 1989; 82: 264-7.
3. Lichter I, Hunt E. The last 48 hours of life. J Palliative Care 1990; 6: 7-15.
4. nd ed. Oxford: Oxford University Press, 1997. p. 977-92.
5. Dudgeon D, Lertzman M. Dyspnea in the advanced cancer patient. J Pain Symptom Manage 1998; 16: 212-9.
6. Escalante CP, Martin CG, Etling LS, Cantor SB, Harle TS, Price KJ, et al. Dyspnea in cancer patients: etiology, resource utilization and survival. Implications in a managed care world. Cancer 1996; 78: 1314-9.
7. Bruera E, Schoeller T, Tun N, Maceachern T, Suárez-Almazor M. Symptomatic benefit of supplemental oxygen in hypoxemic patients with advanced cancer. J Pall Care 1992; 8: 68.
8. rd ed. Oxford: Oxford University Press 1995. p. 39-40.
9. LeGrand SB, Walsh D. Palliative management of dyspnea in advanced cancer. Curr Opin Oncol 1999; 11: 250-4.
10. Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea and ventilatory function in elderly patients with advanced cancer. A randomized double-blind controlled trial. Ann Oncol 1999; 10: 1511-4.
11. Boyd KJ, Kelly M. Oral morphine as symptomatic treatment of dyspnoea in patients with advanced cancer. Palliat Med 1997; 11: 277-81.
12. Zeppetella G. Nebulized morphine in the palliation of dyspnea. Palliat Med 1997; 11: 267-75.
13. Davis C. The role of nebulized drugs in palliating respiratory symptoms in malignant disease. Eur J Palliat Care 1995; 2: 9-15.
14. Farncombe M, Chater S. Clinical application of nebulized opioids for treatment of dyspnea in patients with malignant disease. Support Care Cancer 1994; 2: 184-7.
15. Farcombe M, Chater S, Gillis A. The use of nebulized opioids for breathlessness: a chart review. Palliat Med 1994; 8: 306-612.
16. Colledo SM. El suministro de cuidados paliativos en Latinoamérica: obstáculos y soluciones. Cancer Pain Release 1996; 9: 1-3.
17. Man GCW, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. Chest 1986; 90: 833-6.
18. Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness: contrasting effects of diazepam and promethazine in pink puffers. British Med J 1981; 283: 343-5.
19. Gift AG, Narvasage G. Validity of the numeric rating scale as a measure of clinical dyspnea. Am J Crit Care 1998; 7: 200-4.
20. Manning H, Schwartzstein R. Mechanism of disease. Pathophysiology of dyspnea. N Engl J Med 1995; 333: 1547-53.
21. Ventafridda V, Ripamonti C, de Conno F, Tamburini M, Cassileth BR. Sympton prevalence and control during cancer patients last days of life. Journal Palliative Care 1990; 6: 7-11.
22. Addington-Hall JM, MacDonald LD, Anderson HR, Freeling P. Dying from cancer: the views of bereaved family and friends about the experience of terminally ill patients. Palliative Medicine 1991; 5: 207-14.
23. Shook JE, Watkins WD, Camporesi EM. Differential roles of opioid receptors in respiration, respiratory disease, and opiate-induced respiratory depression. American Review of Respiratory Diseases 1990; 142: 895-909.
24. Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. effects of oxygen on dyspnea in hypoxemic terminal-cancer patients. Lancet 1993; 342: 43-14.
25. Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? Am J Respir Crit Care Med 1996; 153: 1515-8.
26. Navigante A, Sauri A, De Cristófaro O, Kirchuk R, Cabalar M. Estudio prospectivo, comparado y aleatorizado entre oxigenoterapia versus clorhidrato de morfina por vía subcutanea en pacientes con cáncer avanzado y disnea IV. Pren Med Argent 1997; 84: 474-6.
27. Curtis EB, Krech R, Walsh TD. Common symptoms in patients with advanced cancer. J Palliat Care 1991; 7: 25-9.